Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab plus platinum chemotherapy followed by surgery or chemoradiotherapy in resectable or borderline resectable stage IIB-IIIB non-small cell lung cancer
2023-503357-35-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Resection rate. Planned start Feb 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503357-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503357-35-00.